Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Leases (2016 - 2023)

Historic Current Leases for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2023 value amounting to $15.3 million.

  • Ascendis Pharma A's Current Leases rose 851.55% to $15.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $15.3 million, marking a year-over-year increase of 851.55%. This contributed to the annual value of $15.3 million for FY2023, which is 851.55% up from last year.
  • Ascendis Pharma A's Current Leases amounted to $15.3 million in Q4 2023, which was up 851.55% from $14.1 million recorded in Q4 2022.
  • In the past 5 years, Ascendis Pharma A's Current Leases ranged from a high of $15.3 million in Q4 2023 and a low of $6.5 million during Q4 2019
  • In the last 5 years, Ascendis Pharma A's Current Leases had a median value of $8.2 million in 2020 and averaged $10.4 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Current Leases plummeted by 215.02% in 2021, and later soared by 7594.7% in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Current Leases stood at $6.5 million in 2019, then rose by 25.25% to $8.2 million in 2020, then fell by 2.15% to $8.0 million in 2021, then skyrocketed by 75.95% to $14.1 million in 2022, then increased by 8.52% to $15.3 million in 2023.
  • Its Current Leases stands at $15.3 million for Q4 2023, versus $14.1 million for Q4 2022 and $8.0 million for Q4 2021.